Adenoviral vectors (Ads) have been evaluated in clinical trials for glioma. However, systemic immunity against the vectors can hamper therapeutic efficacy. We demonstrated that combined immunostimulation and cytotoxic gene therapy provides long-term survival in preclinical glioma models. Because helper-dependent high-capacity Ads (HC-Ads) elicit sustained transgene expression, in the presence of antiadenoviral immunity, we engineered HC-Ads encoding conditional cytotoxic herpes simplex type 1 thymidine kinase and immunostimulatory cytokine Fms-like tyrosine kinase ligand-3 under the control of the TetOn system. Escalating doses of combined HC-Ads (1×108, 1×109, and 1×1010 viral particles [VP]) were delivered into the rat brain. We assessed neuropathology, biodistribution, transgene expression, systemic toxicity, and behavioral impact at acute and chronic time points after vector delivery. Histopathological analysis did not reveal any evidence of toxicity or long-term inflammation at the lower doses tested. Vector genomes were restricted to the injection site. Serum chemistry did not uncover adverse systemic side effects at any of the doses tested. Taken together, our data indicate that doses of up to 1×109 VP of each HC-Ad can be safely administered into the normal brain. This comprehensive toxicity and biodistribution study will lay the foundations for implementation of a phase 1 clinical trial for GBM using HC-Ads.
Muhammad and colleagues engineer High-Capacity Adenoviral vectors (HC-Ads) encoding conditional cytotoxic herpes simplex type 1 thymidine kinase and immunostimulatory cytokine fms-like tyrosine kinase ligand 3 under the control of the Tetracycline On system and administer escalating doses of combined vector into the rat brain. Comprehensive toxicity and biodistribution studies showed that doses up to 1×109 vp per HC-Ad were safely tolerated in normal brains.
Instructions for Authors can be found on our website at
AliS., CurtinJ.F., ZirgerJ.M.et al.2004. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): Treatment with hsFlt3L inhibits intracranial glioma progression. Mol. Ther., 10:1071–1084.
2.
AliS., KingG.D., CurtinJ.F.et al.2005. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res., 65:7194–7204.
3.
BarciaC., GerdesC., XiongW.D.et al.2006. Immunological thresholds in neurological gene therapy: Highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. Neuron Glia Biol., 2:309–322.
4.
BarciaC., Jimenez-DalmaroniM., KroegerK.M.et al.2007. One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol. Ther., 15:2154–2163.
5.
CandolfiM., CurtinJ.F., XiongW.D.et al.2006. Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol. Ther., 14:371–381.
6.
CandolfiM., CurtinJ.F., NicholsW.S.et al.2007. Intracranial glioblastoma models in preclinical neuro-oncology: Neuropathological characterization and tumor progression. J. Neurooncol., 85:133–148.
7.
CandolfiM., YagizK., FouladD.et al.2009. Release of HMGB1 in response to proapoptotic glioma killing strategies: Efficacy and neurotoxicity. Clin. Cancer Res., 15:4401–4414.
8.
CastroM.G., CandolfiM., KroegerK.et al.2011. Gene therapy and targeted toxins for glioma. Curr. Gene Ther., 11:155–180.
9.
CharlesN.A., HollandE.C., GilbertsonR.et al.2011. The brain tumor microenvironment. Glia, 59:1169–1180.
10.
ChirmuleN., PropertK., MagosinS.et al.1999. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther., 6:1574–1583.
11.
CowsillC., SouthgateT.D., MorrisseyG.et al.2000. Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: Reduced cytotoxicity of a truncated HSV1-TK. Gene Ther., 7:679–685.
12.
CurtinJ.F., KingG.D., BarciaC.et al.2006. Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J. Immunol., 176:3566–3577.
13.
CurtinJ.F., CandolfiM., XiongW.et al.2008. Turning the gene tap off: Implications of regulating gene expression for cancer therapeutics. Mol. Cancer Ther., 7:439–448.
DeweyR.A., MorrisseyG., CowsillC.M.et al.1999. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials. Nat. Med., 5:1256–1263.
16.
GerdesC.A., CastroM.G., LowensteinP.R.2000. Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. Mol. Ther., 2:330–338.
17.
Ghulam MuhammadA.K., CandolfiM., KingG.D.et al.2009. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: Humoral and cellular immunity lead to tumor regression. Clin. Cancer Res., 15:6113–6127.
18.
Gonzalez-AparicioM., AlzugurenP., MauleonI.et al.2011. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut, 60:341–349.
19.
GrossmanS.A., YeX., PiantadosiS.et al.2010. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res., 16:2443–2449.
20.
HeimbergerA.B., SampsonJ.H.2011. Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?Neuro. Oncol., 13:3–13.
21.
Hurtado-LorenzoA., DavidA., ThomasC.et al.2003. Use of recombinant adenovirus for gene transfer into the rat brain: Evaluation of gene transfer efficiency, toxicity, and inflammatory and immune reactions. Methods Mol. Med., 76:113–133.
22.
ImmonenA., VapalahtiM., TyynelaK.et al.2004. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther., 10:967–972.
KingG.D., KroegerK.M., BreseeC.J.et al.2008a. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol. Ther., 16:682–690.
25.
KingG.D., MuhammadA.K., CurtinJ.F.et al.2008b. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro. Oncol., 10:19–31.
26.
KingG.D., MuhammadA.K., XiongW.et al.2008c. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. J. Virol., 82:4680–4684.
27.
KingG.D., MuhammadA.K., LarocqueD.et al.2011. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol. Ther., 19:1793–1801.
28.
LamartinaS., CiminoM., RoscilliG.et al.2007. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: Stable gene transfer, regulated gene expression and therapeutic efficacy. J. Gene Med., 9:862–874.
29.
LorussoG., RueggC.2008. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol., 130:1091–1103.
30.
LowensteinP.R., CastroM.G.2003. Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: Peculiarities, mechanisms, and consequences. Gene Ther., 10:946–954.
31.
LowensteinP.R., CastroM.G.2004. Recent advances in the pharmacology of neurological gene therapy. Curr. Opin. Pharmacol., 4:91–97.
32.
MarkertJ.M., LiechtyP.G., WangW.et al.2009. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM. Mol. Ther., 17:199–207.
33.
McCormackW.M.Jr., SeilerM.P., BertinT.K.et al.2006. Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model. J. Thromb. Haemost., 4:1218–1225.
34.
MineharuY., KingG.D., MuhammadA.K.et al.2011. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin. Cancer Res., 17:4705–4718.
35.
MorralN., O'NealW., RiceK.et al.1999. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. U.S.A., 96:12816–12821.
36.
MuhammadA.K., PuntelM., CandolfiM.et al.2010. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clin. Pharmacol. Ther., 88:204–213.
37.
NgP., BeauchampC., EveleghC.et al.2001. Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Mol. Ther., 3:809–815.
38.
NwanegboE., VardasE., GaoW.et al.2004. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol., 11:351–357.
39.
OkaK., BelalcazarL.M., DiekerC.et al.2007. Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector. Gene Ther., 14:191–202.
40.
PalmerD., NgP.2003. Improved system for helper-dependent adenoviral vector production. Mol. Ther., 8:846–852.
41.
PalmerD.J., NgP.2004. Physical and infectious titers of helper-dependent adenoviral vectors: A method of direct comparison to the adenovirus reference material. Mol. Ther., 10:792–798.
PalmerD.J., NgP.2011. Rescue, amplification, and large-scale production of helper-dependent adenoviral vectors. Cold Spring Harb. Protoc., 2011:857–866.
44.
ParksR.J., ChenL., AntonM.et al.1996. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A., 93:13565–13570.
45.
PietrasK., OstmanA.2010. Hallmarks of cancer: Interactions with the tumor stroma. Exp. Cell Res., 316:1324–1331.
46.
PuntelM., CurtinJ.F., ZirgerJ.M.et al.2006. Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. Hum. Gene Ther., 17:531–544.
47.
PuntelM., KroegerK.M., SandersonN.S.et al.2010a. Gene transfer into rat brain using adenoviral vectors. Curr. Protoc. Neurosci.Chapter 4, Unit 4.24.
48.
PuntelM., MuhammadA.K., CandolfiM.et al.2010b. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and Tet-inducible expression of Flt3L for glioma therapeutics. J. Virol., 84:6007–6017.
49.
SchiednerG., MorralN., ParksR.J.et al.1998. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet., 18:180–183.
50.
SchillingerK.J., TsaiS.Y., TaffetG.E.et al.2005. Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc. Natl. Acad. Sci. U.S.A., 102:13789–13794.
51.
StuppR., MasonW.P., Van Den BentM.J.et al.2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 352:987–996.
52.
SulJ., FineH.A.2010. Malignant gliomas: New translational therapies. Mt. Sinai J. Med., 77:655–666.
53.
SumidaS.M., TruittD.M., LemckertA.A.et al.2005. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol., 174:7179–7185.
54.
SunC., ZhangY., FengL.et al.2011. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine, 29:3837–3841.
55.
SzaboA.T., CarpentierA.F.2011. Immunotherapy in human glioblastoma. Rev. Neurol. (Paris), 167:668–672.
56.
TerashimaT., OkaK., KritzA.B.et al.2009. DRG-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice. J. Clin. Invest., 119:2100–2112.
57.
ThomasC.E., SchiednerG., KochanekS.et al.2000. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: Toward realistic long-term neurological gene therapy for chronic diseases. Proc. Natl. Acad. Sci. U.S.A., 97:7482–7487.
58.
ThomasC.E., BirkettD., AnozieI.et al.2001a. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol. Ther., 3:36–46.
59.
ThomasC.E., SchiednerG., KochanekS.et al.2001b. Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum. Gene Ther., 12:839–846.
60.
ToiettaG., ManeV.P., NoronaW.S.et al.2005. Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc. Natl. Acad. Sci. U.S.A., 102:3930–3935.
61.
VauleonE., AvrilT., ColletB.et al.2010. Overview of cellular immunotherapy for patients with glioblastoma. Clin. Dev. Immunol., 2010:689171.
62.
WellerM.2011. Novel diagnostic and therapeutic approaches to malignant glioma. Swiss Med. Wkly., 141:w13210.
63.
XiongW., GoverdhanaS., SciasciaS.A.et al.2006. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J. Virol., 80:27–37.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
